Stocks Overview

LAST PRICE
37.0000
TODAY'S CHANGE (%)
0.0000 (0.0000%)

Bid / Lots
---/ ---
Ask / Lots
---/ ---
Open / Previous Close
0.0000 / 37.0000
Day Range
---
52 Week Range
Low 27.9850
High 50.9900
Volume
---
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TSX Comp
TSX Venture
DJIA
S&P 500
NASDAQ

Price Comparison Graph. See accessible table below

1 Day Comparison Chart Accessibility Table. Monday's close: 37.41
Time	Volume	XENE
09:32 ET	10717	37.3
09:34 ET	100	36.7
09:38 ET	100	36.73
09:39 ET	200	36.81
09:43 ET	300	37.11
09:45 ET	600	37.23
09:48 ET	100	37.25
09:52 ET	2500	37.205
09:54 ET	100	37.16
09:56 ET	100	37.455
09:57 ET	100	37.29
09:59 ET	17194	37.4185
10:01 ET	3628	37.205
10:03 ET	2655	37.2994
10:06 ET	10142	37.63
10:08 ET	100	37.49
10:10 ET	100	37.33
10:12 ET	100	37.405
10:14 ET	300	37.375
10:15 ET	600	37.26
10:17 ET	655	37.27
10:19 ET	1600	37.315
10:21 ET	609	37.29
10:24 ET	6145	37.35
10:26 ET	400	37.33
10:28 ET	300	37.235
10:30 ET	400	37.25
10:32 ET	500	37.14
10:33 ET	2775	37.21
10:35 ET	686	37.2
10:37 ET	200	37.205
10:39 ET	300	37.15
10:42 ET	400	37.14
10:44 ET	1200	37.23
10:46 ET	100	37.2
10:48 ET	200	37.235
10:50 ET	100	37.19
10:51 ET	500	37.24
10:55 ET	1219	37.35
10:57 ET	700	37.335
11:00 ET	400	37.39
11:02 ET	200	37.295
11:04 ET	726	37.325
11:06 ET	810	37.38
11:08 ET	2232	37.36
11:09 ET	2306	37.46
11:11 ET	100	37.34
11:13 ET	100	37.39
11:15 ET	400	37.385
11:18 ET	1535	37.4325
11:20 ET	100	37.43
11:22 ET	1236	37.36
11:24 ET	200	37.31
11:26 ET	300	37.355
11:27 ET	100	37.31
11:29 ET	236	37.32
11:31 ET	9569	37.41
11:33 ET	500	37.31
11:38 ET	300	37.29
11:40 ET	300	37.235
11:42 ET	400	37.26
11:44 ET	1300	37.225
11:47 ET	300	37.22
11:49 ET	200	37.15
11:51 ET	200	37.14
11:54 ET	100	37.13
11:58 ET	2732	37.175
12:00 ET	1000	37.13
12:02 ET	900	37.15
12:03 ET	660	37.22
12:07 ET	300	37.225
12:09 ET	100	37.2
12:12 ET	100	37.26
12:14 ET	1474	37.385
12:16 ET	300	37.335
12:20 ET	1000	37.31
12:21 ET	1600	37.25
12:23 ET	1030	37.17
12:25 ET	100	37.19
12:27 ET	100	37.215
12:30 ET	306	37.205
12:32 ET	804	37.255
12:34 ET	204	37.245
12:36 ET	1024	37.27
12:38 ET	200	37.25
12:39 ET	231	37.19
12:41 ET	400	37.2
12:43 ET	300	37.26
12:45 ET	300	37.25
12:48 ET	1336	37.28
12:50 ET	749	37.32
12:52 ET	600	37.38
12:56 ET	200	37.33
12:57 ET	200	37.37
12:59 ET	100	37.35
01:01 ET	600	37.32
01:03 ET	917	37.3
01:06 ET	200	37.315
01:08 ET	300	37.22
01:10 ET	253	37.32
01:12 ET	100	37.31
01:14 ET	100	37.32
01:15 ET	100	37.28
01:17 ET	100	37.29
01:19 ET	500	37.325
01:21 ET	300	37.31
01:24 ET	236	37.33
01:26 ET	355	37.33
01:28 ET	996	37.39
01:30 ET	1000	37.37
01:32 ET	676	37.3
01:33 ET	200	37.31
01:37 ET	512	37.295
01:39 ET	100	37.3
01:42 ET	100	37.26
01:44 ET	700	37.34
01:48 ET	600	37.3
01:50 ET	922	37.28
01:51 ET	1415	37.235
01:53 ET	400	37.235
01:55 ET	1539	37.27
01:57 ET	387	37.275
02:00 ET	200	37.25
02:02 ET	402	37.26
02:04 ET	2300	37.35
02:06 ET	200	37.3
02:08 ET	536	37.27
02:09 ET	100	37.27
02:11 ET	100	37.33
02:13 ET	300	37.33
02:15 ET	300	37.3
02:18 ET	1300	37.285
02:20 ET	100	37.27
02:22 ET	887	37.24
02:24 ET	100	37.25
02:26 ET	100	37.24
02:27 ET	700	37.27
02:29 ET	400	37.26
02:31 ET	1973	37.13
02:33 ET	1240	37.085
02:36 ET	200	37.03
02:38 ET	2000	37.085
02:40 ET	600	37.105
02:44 ET	200	37.085
02:45 ET	700	37.0775
02:47 ET	900	37.03
02:49 ET	2643	37.07
02:51 ET	4768	37.06
02:54 ET	323	37.07
02:56 ET	1813	37.12
02:58 ET	1399	37.08
03:00 ET	1300	37.07
03:02 ET	300	37.05
03:03 ET	1435	37.02
03:05 ET	1852	36.9
03:09 ET	1050	36.89
03:12 ET	100	36.88
03:14 ET	440	36.88
03:16 ET	2470	36.99
03:18 ET	1100	36.95
03:20 ET	400	36.97
03:21 ET	107388	36.875
03:25 ET	1000	36.93
03:27 ET	100	36.93
03:30 ET	800	36.89
03:32 ET	300	36.93
03:34 ET	1900	36.8
03:36 ET	400	36.765
03:38 ET	297	36.77
03:39 ET	1500	36.71
03:41 ET	2308	36.73
03:43 ET	316	36.71
03:45 ET	3433	36.64
03:48 ET	1500	36.61
03:50 ET	1392	36.63
03:52 ET	3050	36.56
03:54 ET	4375	36.66
03:56 ET	25326	36.66
03:57 ET	52213	37.06
03:59 ET	58739	37

Data delayed at least 15 minutes.

Jun 18, 2024
- DJ Xenon Pharmaceuticals Price Target Maintained With a $55.00/Share by RBC Capital, from 8:59AM ET on Tuesday Jun 18, 2024 by Dow Jones
  8:59AM ET on Tuesday Jun 18, 2024 by Dow Jones
Jun 5, 2024
- Xenon Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference, from 4:01PM ET on Wednesday Jun 05, 2024 by Dow Jones
  4:01PM ET on Wednesday Jun 05, 2024 by Dow Jones
May 28, 2024
- Xenon Pharmaceuticals Presents Data from Phase 2 X-NOVA Clinical Trial of Azetukalner in Major Depressive Disorder at the American Society of Clinical Psychopharmacology 2024 Annual Meeting, from 8:30AM ET on Tuesday May 28, 2024 by Dow Jones
  8:30AM ET on Tuesday May 28, 2024 by Dow Jones

0 New Today

Industry Peers Overview Table
Company sortable	Market Cap sortable	P/E Ratio (TTM) sortable	EPS Growth (5yr) sortable
United StatesXENE Xenon Pharmaceuticals Inc	2.8B	-13.6x	---
United StatesGERN Geron Corp	2.7B	-13.1x	---
United StatesIDYA IDEAYA Biosciences Inc	2.8B	-18.1x	---
United StatesSWTX SpringWorks Therapeutics Inc	2.7B	-7.1x	---
United StatesBHVN Biohaven Ltd	3.1B	-5.1x	---
United StatesVSBC Vitaspring Biomedical Co. Ltd	3.1B	3,311.3x	---
As of 2024-06-26

Xenon Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company focused on developing therapeutics to improve the lives of patients with neurological disorders, with a focus on epilepsy. The Company’s product pipeline includes XEN1101 (Focal Onset Seizures), XEN1101 (Primary Generalized Tonic-Clonic Seizures), XEN1101 (Major Depressive Disorder) and NBI-921352 (NEUROCRINE). It is developing XEN1101, a differentiated Kv7 potassium channel opener, for the treatment of epilepsy, MDD and potentially other neurological disorders. Its XEN1101 Phase III epilepsy program includes two identical Phase III clinical trials, called X-TOLE2 and X-TOLE3, that are designed closely after the Phase IIb X-TOLE clinical trial. Its Phase III X-ACKT clinical trial is intended to support potential regulatory submissions in an additional epilepsy indication of primary generalized tonic-clonic seizures (PGTCS).

Contact Information

Headquarters: 3650 Gilmore WayVANCOUVER, BC, Canada V5G 4W8
Phone: 604-484-3300
Fax: 604-484-3450

Executives

Chairman of the Board: Simon Pimstone
President, Chief Executive Officer, Director: Ian Mortimer
Chief Financial Officer: Sherry Aulin
Executive Vice President - Drug Discovery: James Empfield
Executive Vice President - Strategy and Innovation: Robin Sherrington

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Skip section

INK Company InsiderDetailed daily analysis of insider activity and holdings for stocks and income trusts listed in Canada, based on filings from SEDI®.

Fundamentals Table
Market Cap	$2.8B
Revenue (TTM)	$0.00
Shares Outstanding	75.5M
Dividend Yield	0.00%
Annual Dividend Rate	---
Ex-Dividend Date	01-01-01
Pay Date	01-01-01
Beta	1.26
EPS	$-2.71
Book Value	$12.31
P/E Ratio	-13.6x
Price/Sales (TTM)	---
Price/Cash Flow (TTM)	---
Operating Margin	---

*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.

Xenon Pharmaceuticals Inc
NASDAQ:XENEUnited States

Search Criteria

Charts

Recent News

Jun 18, 2024

DJ Xenon Pharmaceuticals Price Target Maintained With a $55.00/Share by RBC Capital, from 8:59AM ET on Tuesday Jun 18, 2024 by Dow Jones

Jun 5, 2024

Xenon Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference, from 4:01PM ET on Wednesday Jun 05, 2024 by Dow Jones

May 28, 2024

Xenon Pharmaceuticals Presents Data from Phase 2 X-NOVA Clinical Trial of Azetukalner in Major Depressive Disorder at the American Society of Clinical Psychopharmacology 2024 Annual Meeting, from 8:30AM ET on Tuesday May 28, 2024 by Dow Jones

Biotechnology Industry Peers

Company Information

Contact Information

Executives

Ratings

Reports

Fundamentals

Calendar